All In Biotech

Drug Trial Radar · NCT02169557

Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study

Last checked: Nov 20, 2026Latest source record: Jun 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Title says "pivotal". This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

230

Actual

Start

Apr 30, 2014

Primary completion

Oct 9, 2016

Study completion Apr 25, 2017

Sponsor

Lead sponsor
Drugs for Neglected DiseasesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 23, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate the treatment success of fexinidazole, at one year follow-up visit, in HAT stage 1 and early stage 2 patients.

Conditions

  • Human African Trypanosomiasis (HAT)

Interventions

  • FexinidazoleDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Outcome (success or failure) at the test of cure (ToC) visit 12 months after the end of treatment (EOT).Time frame: 12 months after end of treatment (day 11)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Kinshasa, Democratic Republic of the Congo

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.